RxDoctor Payments Data

David Levine, MD

Gynecology · Saint Louis, MONPI 1922025444

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $172,530 of the $201,351 with a category attached, or 85.7%. Gynesonics, Inc. accounts for 94.6% of it on its own, with 22 other manufacturers making up the rest. Reporting peaked in 2022 at $65,178 and has fallen 73.3% since, to $17,402 in 2025. Among gynecology clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$201,351in general payments, 2019–2025

Across 191 payments — averaging $1054.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gynesonics, Inc.$190K
  • Hologic Sales And Service, LLC$8K
  • Cytyc Surgical Products, LLC$1K
  • AbbVie$399
  • Sumitomo Pharma America, Inc.$297
  • Astellas Pharma US Inc$155
  • plus $686 from 17 others
$79,251in research payments, 2019–2025

Across 17 payments — averaging $4661.80 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Gynesonics, Inc.$76K
  • Aegea Medical, Inc.$3K
  • Acessa Health Inc.$313

What the payments were for

  • Consulting fees$172,53086%
  • Travel & lodging$22,40411%
  • Food & beverage$6,2953%
  • Education$1230%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$201,351 in reported general payments places this provider in the 95th percentile of 38 gynecology providers in Missouri.

See all gynecology providers in Missouri

Medicare billing

Part B allowed, 2024
$7,217
Medicare patients
65
Services billed
81

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron24$15,276
PremarinEstrogens, Conjugated15$6,366
Estradiol79$3,798
Estradiol (Twice Weekly)Estradiol28$2,998
Medroxyprogesterone Acetate14$162
Fluconazole14$43

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$155$15,27624 claims
PfizerPremarin$114$6,36615 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 38 gynecology providers in Missouri.

Other gynecology in Saint Louis

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →